Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 TOTAL COMPANY REVENUES OF $306.0 MILLION FOR THE FIRST QUARTER OF 2026 BRINSUPRI  (BRENSOCATIB) REVENUES OF $207.9 MILLION FOR THE FIRST QUARTER OF 2026, REFLECTING 44% GROWTH OVER THE FOURTH QUARTER OF 2025  ARIKAYCE  (AMIKACIN LIPOSOME INHALATION SUSPENSION) REVENUES OF $98.1 MILLION FOR THE FIRST QUARTER OF 2026, REFLECTING 6% GROWTH OVER THE FIRST QUARTER OF 2025 COMPANY REITERATES 2026 BRINSUPRI REVENUE GUIDANCE OF AT LEAST $1 BILLION AND 2026 ARIKAYCE REVENUE GUIDANCE OF $450 MILLION TO $470 MILLION  PHASE 3B ENCORE STUDY OF ARIKAYCE IN PATIENTS WITH MAC LUNG DISEASE MET PRIMARY AND ALL MULTIPLICITY-CONTROLLED SECONDARY CULTURE CONVERSION ENDPOINTS PHASE 3 PALM-PAH STUDY OF TPIP IN PATIENTS WITH PAH INITIATED IN APRIL 2026 BRIDGEWATER, N.J., MAY 7, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

 INSMED'S EDUCATIONAL INITIATIVE, SUSPECT BRONCHIECTASIS(SUSPECT BE), AIMS TO ELEVATE RECOGNITION AND DIAGNOSIS OF BRONCHIECTASIS AND ENCOURAGE CONVERSATIONS WITH A PULMONOLOGIST   BRONCHIECTASIS SYMPTOMS OFTEN OVERLAP WITH COPD OR ASTHMA AND MAY GO UNRECOGNIZED FOR YEARS, HIGHLIGHTING THE NEED TO LOOK DEEPER AT RESPIRATORY SYMPTOMS   TV PERSONALITY, TY PENNINGTON, BRINGS VISIBILITY TO THE CHRONIC LUNG CONDITION THROUGH HIS EXPERIENCE CARING FOR HIS MOTHER, WHO IS LIVING WITH BRONCHIECTASIS  BRIDGEWATER, N.J., MAY 6, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED A COLLABORATION WITH EMMYAWARDWINNING TV HOST, DESIGNER, AND CARPENTER, TY PENNINGTON, TO LAUNCHSUSPECT BRONCHIECTASIS(SUSPECT BE).

INSMED AND TY PENNINGTON TEAM UP TO DRIVE AWARENESS AND PROPER DIAGNOSIS OF BRONCHIECTASIS

NEW DATA IN NON-CYSTIC FIBROSIS BRONCHIECTASIS FURTHER DEFINE IMPACT OF BRINSUPRI  ON RESPIRATORY SYMPTOMS FINDINGS FROM A PHARMACOKINETIC STUDY CONTINUE TO SUPPORT FURTHER EVALUATION OF TREPROSTINIL PALMITIL INHALATION POWDER PHASE 3 DEVELOPMENT PROGRAM ADDITIONALLY, INSMED PROVIDES INDEPENDENT RESEARCH GRANT TO THE AMERICAN THORACIC SOCIETY FOR A LANDMARK QUALITY INITIATIVE TO IMPROVE DIAGNOSIS OF BRONCHIECTASIS ACROSS THE U.S. BRIDGEWATER, N.J., MAY 4, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT SIX ABSTRACTS FROM ACROSS ITS RESPIRATORY PORTFOLIO AND PIPELINE AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE 2026 (ATS 2026), TAKING PLACE MAY 1720 IN ORLANDO, FLORIDA.

INSMED TO PRESENT DATA ACROSS ITS RESPIRATORY PORTFOLIO, INCLUDING LATE-BREAKING ARIKAYCE RESULTS FROM PHASE 3B ENCORE STUDY, AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE 2026

BRIDGEWATER, N.J., APRIL 30, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: BOFA SECURITIES 2026 HEALTHCARE CONFERENCE IN LAS VEGAS ON TUESDAY, MAY 12, 2026, AT 1:40 P.M.

INSMED TO PRESENT AT MAY 2026 INVESTOR CONFERENCES

BRIDGEWATER, N.J., APRIL 23, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FIRST-QUARTER 2026 FINANCIAL RESULTS ONTHURSDAY, MAY 7, 2026.

INSMED TO HOST FIRST-QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, MAY 7, 2026

STUDY DID NOT MEETPRIMARY OR SECONDARY EFFICACYENDPOINTS; INSMED WILL DISCONTINUE HS PROGRAM SAFETY WAS CONSISTENT WITHPREVIOUS STUDIES AND NO NEW SAFETY SIGNALS WERE IDENTIFIED FOR EITHER DOSE OF BRENSOCATIB BRIDGEWATER, N.J., APRIL 7, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT THE PHASE 2B CEDAR STUDY, WHICH EVALUATED BRENSOCATIB IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS), DID NOT MEET ITS PRIMARY OR SECONDARY EFFICACY ENDPOINTS IN EITHER THE 10 MG OR 40 MG TREATMENT ARMS.

INSMED PROVIDES CLINICAL UPDATE ON PHASE 2B CEDAR STUDY

THE STUDY MET PRIMARY AND ALL MULTIPLICITY-CONTROLLED SECONDARY CULTURE CONVERSION ENDPOINTS, DEMONSTRATING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN RESPIRATORY SYMPTOM SCORE AND CULTURE CONVERSION RATES IN THE SECOND HALF OF 2026, INSMED PLANS TO FILE A SUPPLEMENTAL NDA FOR ARIKAYCE WITH THE FDA AND SUBMIT THE DATA TO THE PMDA IN JAPAN TO SUPPORT POTENTIAL LABEL CHANGES INSMED TO HOST INVESTOR CONFERENCE CALL ON MONDAY, MARCH 23, 2026, AT 8:00 AM ET BRIDGEWATER, N.J., MARCH 23, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3B ENCORE STUDY.

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3B ENCORE STUDY OF ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH MAC LUNG DISEASE

BRIDGEWATER, N.J., MARCH 5, 2026 /PRNEWSWIRE/ --INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO 85 NEW EMPLOYEES.

INSMED REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

COMPANY EXPECTS FULL-YEAR 2026 BRINSUPRI (BRENSOCATIB) REVENUES TO BE AT LEAST $1 BILLION; REITERATES FULL-YEAR 2026 ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) REVENUE GUIDANCE OF$450 MILLIONTO$470 MILLION TOTAL COMPANY REVENUES OF $606.4 MILLION FOR FULL-YEAR 2025 BRINSUPRI TOTAL REVENUES OF $144.6 MILLION FOR FOURTH-QUARTER AND $172.7 MILLION FOR FULL-YEAR 2025 ARIKAYCETOTAL REVENUES OF$119.2 MILLION FOR FOURTH-QUARTER AND $433.8MILLION FOR FULL-YEAR 2025, REPRESENTING 19% ANNUAL GROWTH AND EXCEEDING THE UPPER END OF FULL-YEAR 2025 GUIDANCE TOPLINE DATA READOUTS FROM PHASE 3 ENCORE AND PHASE 2B CEDAR STUDIES REMAIN ON TRACK FDA GRANTS ORPHAN DRUG DESIGNATION TO TREPROSTINIL PALMITIL FOR TREATMENT OF PAH COMPANY ENDS 2025 WITH APPROXIMATELY $1.4 BILLION OF CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES BRIDGEWATER, N.J., FEB. 19, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., FEB. 13, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: 46TH ANNUAL TD COWEN HEALTHCARE CONFERENCE IN BOSTON, ON MONDAY, MARCH 2, 2026, AT 9:50 A.M.

Insmed Incorporated

INSM

Price

Financial Reports

No items found.

Press Releases

Insmed Incorporated

INSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INSM